NOACs versus warfarin for stroke prevention in patients with AF : a systematic review and meta-analysis by Hicks, Tim et al.
NOACs versus warfarin for stroke
prevention in patients with AF:
a systematic review and meta-analysis
Tim Hicks,1 Fiona Stewart,2 Anne Eisinga3
To cite: Hicks T, Stewart F,
Eisinga A. NOACs versus
warfarin for stroke prevention
in patients with AF:
a systematic review and
meta-analysis. Open Heart
2016;3:e000279.
doi:10.1136/openhrt-2015-
000279
▸ Additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/openhrt-2015-
000279).
Received 10 April 2015
Revised 11 December 2015
Accepted 14 December 2015
1Dorset County Hospital,
Dorchester, UK
2Health Services Research
Unit, University of Aberdeen,
Aberdeen, UK
3UK Cochrane Centre, Oxford,
UK
Correspondence to
Dr Tim Hicks;
tim.hicks.09@aberdeen.ac.uk
ABSTRACT
Background: Warfarin has been the anticoagulant of
choice for the prevention of ischaemic stroke in
patients with atrial fibrillation (AF). Novel oral
anticoagulants (NOACs) are increasingly used as an
alternative.
Objectives: The objective of this review was to
evaluate the efficacy and safety of the NOACs versus
warfarin in patients with AF.
Search methods: Medline, EMBASE and grey
literature search for all phase II and III randomised
control trials.
Data collection/analysis: Two authors
independently reviewed abstracts and performed data
extraction of eligible full-text articles. Revman V.5 was
used for meta-analysis.
Main results: 12 studies were identified with a total
study population of 77 011. NOACs demonstrated a
reduction in the composite of stroke or systemic
embolic events OR 0.85 (95% CI 0.75 to 0.98), a 52%
reduction in intracranial haemorrhage OR 0.48 (95% CI
0.40 to 0.57) and a 14% reduction in mortality OR
0.86 (0.82 to 0.91). The 30-day end of study switch to
warfarin demonstrated an in increase in stroke or
systemic embolic events OR 2.60 (95% CI 1.61 to
4.18) and an increase in major bleeding OR 2.19 (95%
CI 1.42 to 3.36).
Conclusions: NOACs are superior to warfarin for the
prevention of the composite of stroke and systemic
embolism in patients with AF and an additional risk
factor for stroke. There is a significant reduction in
intracranial haemorrhage, which drives the finding of
significantly lower mortality. During the poststudy
switch from NOACs to warfarin there is an excess of
the composite of stroke and systemic embolism as well
as major bleeding events, which may be of significance
in clinical practice.
INTRODUCTION
Description of the condition
Atrial ﬁbrillation is a common arrhythmia with
a less efﬁcient passage of blood through the
atria with the potential for stasis and increased
risk of thrombus formation particularly in the
atrial appendage. This thrombus formation
gives rise to the potential for embolism, which
can manifest as ischaemic stroke.1 2
Description of control/comparison
Warfarin is a vitamin K antagonist, which
exerts its anticoagulant effect by inhibiting the
clotting factors II, VII, IX and X. Regrettably, it
is, however, prone to numerous drug and food
interactions,3 which necessitates regular blood
testing to maintain the international normal-
isation ratio (INR) within the therapeutic
range. Signiﬁcant patient time and medical
resources are required and the effective vigi-
lance of medical practitioners in the bespoke
tailoring of warfarin dose to the individual is
far from straight forward.
KEY QUESTIONS
What is already known about this subject?
▸ Factor Xa inhibitors and direct thrombin (factor
IIa) inhibitors, novel oral anticoagulants (NOACs)
are effective in the prevention of ischaemic
stroke in patients with atrial fibrillation and at
least one additional risk factor for stroke when
compared to warfarin.
What does this study add?
▸ This is an independent meta-analysis of all
phase II and III clinical trials with 77 011 parti-
cipants, which additionally demonstrates a
reduction in the composite of stroke and sys-
temic embolism, a halving of the number of
haemorrhagic strokes, which drives a reduction
in all-cause mortality.
▸ During the 30-day poststudy switch from NOACs
to warfarin there is an increase in the composite
of stroke and systemic embolism as well as
major bleeding.
How might this impact on clinical practice?
▸ NOACs could progress to being the first-line
therapy for stroke prevention in patients with
atrial fibrillation and at least one additional risk
factor for stroke.
▸ Thromboembolic and bleeding events within
30 days of discontinuation of NOACs and switch
to warfarin should be considered as adverse
events and highlighted through the reporting
system of the clinician’s country of practice.
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Description of the intervention and how it might work
Novel oral anticoagulants (NOACs) have a more speciﬁc
mode of action directly targeting just one clotting factor.
The factor Xa inhibitors and direct thrombin (factor
IIa) inhibitors produce a more predictable and less
labile anticoagulant effect, which is less susceptible to
drug and food interactions and do not require regular
monitoring.
Why it is important to do this review
There have been several reviews addressing similar inter-
ventions and outcomes,4–6 however, this review is an
independent review, which aimed to identify all NOACs
with high-quality phase II and III trials. In addition this
review evaluated data from the end of the clinical trials
when NOACs are stopped and participants are switched
to warfarin. This has mostly gone unreported and is a
key element of understanding the place of NOACs and
particularly relevant considering the extent of discon-
tinuation of around 20–24% in the clinical trial setting.
This review also applied the Grading of
Recommendations, Assessment, Development and
Evaluation (GRADE) criteria for assessing the strength
of evidence in a summary of ﬁndings table.
Objectives
1. To evaluate the efﬁcacy and safety of the NOACs with
warfarin as a comparator as well as the end of trial
‘switch’ to warfarin in patients with atrial ﬁbrillation
and an additional risk factor for stroke.
2. To formulate a GRADE summary of ﬁndings table.
METHODS
The review was conducted in accordance with PRISMA
guidelines and an a priori protocol for the review was
registered with Prospero.7
Literature search, eligibility criteria and data collection
Highly sensitive electronic searches were conducted to
identify randomised control trials comparing NOACs to
warfarin. The databases searched were: MEDLINE (1946
to March week 3 2014), MEDLINE-In-Process and other
non-indexed Citations(31 March 2014), Embase
(OvidSP 1974 to 2014 April 01, The Cochrane Library
(Issue 4, April 2014), Cochrane Central Register of
Controlled Trials (Issue 1, January 2014), Database of
Abstracts of Reviews of Effects (Issue 1, January 2014),
Latin American and Caribbean Health Sciences
(LILACS) (April 2014) and Scopus (April 2014). No lan-
guage or date restrictions were imposed on the search.
Reference lists of included studies were checked to iden-
tify further relevant articles. Additionally, recent confer-
ence proceedings of the European Society of
Cardiology, European Haematology Association and
American Society of Hematology and websites of
pharmaceutical manufacturers were searched. Study
authors were contacted to request additional data or to
seek clariﬁcation where information in the published
report was lacking or ambiguous.
Two reviewers independently screened the titles and
abstracts identiﬁed by the literature search. Full-text
papers selected from the search results were also inde-
pendently screened by two reviewers. Any disagreements
were resolved by consensus. After developing and pilot-
ing a data extraction form, data were extracted from the
included studies by one reviewer and checked by a
second.
Quality assessment was carried out using the Cochrane
Collaboration’s tool for assessing risk of bias (ROB) (see
online supplementary appendix ﬁgures 3 and 4). The
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) evidence quality assessment
tool was used to assess outcomes across studies.
Statistical analysis
Data were imported into Review Manager V.5.2 (The
Cochrane Collaboration, Oxford) for quantitative syn-
thesis. Dichotomous outcomes were converted from HRs
or risk ratios (RR) to ORs, with 95% CIs. Heterogeneity
between studies was assessed by visual inspection of plots
of the data, the χ2 test for heterogeneity, and the I2
statistic.8
Fixed effects meta-analyses were undertaken where
statistical heterogeneity was judged to be low. Where stat-
istical heterogeneity was moderate to high, random
effects meta-analyses were undertaken to take into
account within study and between study variability.
When included studies had multiple intervention
arms comparing different doses of NOAC s with a single
comparison arm of warfarin, the smaller phase II study
the data for the NOACs arms was combined to produce
a single summary statistic for comparison with the war-
farin arm. For larger phase III studies with more than
one dose of NOACs, the number of participants and
events in the warfarin arms were divided evenly into the
same number of corresponding NOACs arms. This
ensures that multiplicity of data does not unduly inﬂu-
ence the pooled effect estimate in the forest plot.
SUMMARY OF RESULTS
Studies identified
Twelve studies along with eight further reports9–28 were
identiﬁed which were suitable for meta-analysis (see
online supplementary appendix ﬁgure 1 and 2). All
were drug company funded. Three were large inter-
national multicentre phase III trials of factor Xa inhibi-
tors, apixaban, rivaroxaban and edoxaban, one was a
smaller study of rivaroxaban with Japanese participants.
All four of studies were high quality low ROB trials with
double blind intervention arms and warfarin control
arms. Outcome assessment was also blinded. There was
one large phase III trial of the direct thrombin (factor
IIa) inhibitor dabigatran.
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Figure 1 Table of pooled results.
Figure 2 Stroke or systemic embolism random effects model.
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There were six phase II trials of factor Xa inhibitors,
edoxaban, betrxiaban, apixaban and YM150 as well as
one phase II trial of the direct thrombin (factor IIa)
inhibitor AZD 0837. The combined total study popula-
tion was 77 011. There was one further study identiﬁed
OPAL-2, which was published as an abstract only with
insufﬁcient study methodology and data.
Correspondence with the authors did not result in
obtaining any further study details.
All stroke and systemic embolism outcomes
There was signiﬁcant heterogeneity for the outcome of
stroke or systemic embolism the ﬁxed effects model OR
0.87 (95% CI 0.81 to 0.95) suggests a signiﬁcant reduction
in stroke and systemic embolism in the NOACs, this
ﬁnding was supported by the random effects model OR
0.85 (95% CI 0.75 to 0.98) (ﬁgures 1 and 2). There was sig-
niﬁcant heterogeneity for the outcome of ischaemic stroke
OR 1.02 (95% CI 0.93 to 1.12) suggesting and equivocal
result this was ﬁnding was supported by the random
effects model OR 0.98 (95% CI 0.82 to 1.16) (ﬁgure 3).
There was a signiﬁcant reduction in intracranial haemor-
rhage OR 0.48 (95% CI 0.0.40 to 0.57) (ﬁgure 4) and mor-
tality OR 0.86 (95% CI 0.82 to 0.91) (ﬁgure 5).
Bleeding outcomes
There was signiﬁcant heterogeneity for the composite
outcome of major bleeding and non-major clinically
relevant bleeding the ﬁxed effects model OR 0.81
(95% CI 0.77 to 0.84) suggests a signiﬁcant reduction
in major bleeding and non-major clinically relevant
bleeding in the NOAC’s, however, the random effects
model showed a non-signiﬁcant trend towards beneﬁt
OR 0.84 (95% CI 0.68 to 1.03). There was signiﬁcant
heterogeneity for the outcome of major bleeding, the
ﬁxed effects model OR 0.78 (95% CI 0.73 to 0.83) sug-
gests a signiﬁcant reduction in major bleeding in the
NOAC’s, this ﬁnding was supported by the random
effects model OR 0.76 (95% CI 0.62 to 0.93). There
was signiﬁcant heterogeneity for the outcome of gastro-
intestinal bleeding, the ﬁxed effects model OR 1.12
(95% CI 1.01 to 1.25) suggests a signiﬁcant increase in
gastrointestinal bleeding in the NOAC’s, however, the
random effects model OR 1.05 (95% CI 0.82 to 1.36)
was equivocal.
Myocardial infarction
There was signiﬁcant heterogeneity for the outcome of
myocardial infarction, the ﬁxed effects model OR 1.02
Figure 3 Ischaemic stroke random effects model.
4 Hicks T, Stewart F, Eisinga A. Open Heart 2016;3:e000279. doi:10.1136/openhrt-2015-000279
Open Heart
group.bmj.com on June 13, 2017 - Published by http://openheart.bmj.com/Downloaded from 
(95% CI 0.90 to 1.15) and the random effects model
OR 1.03 (95% CI 0.88 to 1.20) indicate an equivocal
result.
30-day end of study switch to warfarin
The 30-day end of study switch to warfarin data was only
reported by the authors of the ROCKET AF, ENGAGE
AF-TIMI 48, ARISTOTLE and J-Rocket AF for the com-
posite outcome of stroke or systemic embolism. The
ﬁxed effects model OR 2.60 (95% CI 1.61 to 4.18) is
suggestive of signiﬁcantly more events in the NOAC’s
arms (ﬁgure 6). The 30-day end of study switch to war-
farin data was only reported by the authors of the
ROCKET AF, ARISTOTLE and ENGAGE AF-TIMI 48 for
major bleeding, the ﬁxed effects model OR 2.19 (95%
CI 1.42 to 3.36) suggests signiﬁcantly more events in the
NOAC’s arms (ﬁgure 7).
Forest plot ﬁxed effects models and where relevant
random effects models not presented here are available
in the online supplementary appendix ﬁgures 5–14.
DISCUSSION
Twelve studies were identiﬁed which were suitable for
synthesis of data and meta-analysis, four phase III trials
and six phase II trials of factor Xa inhibitors as well as
one phase III trial and one phase II trial of direct throm-
bin (factor IIa) inhibitors with a total study population
of 77 011. A further eight supplementary publications
providing further insight into the methodology and out-
comes were also used to augment the accuracy of this
meta-analysis.
All studies included were well conducted randomised
controlled trials. Four were double blind trials with a
method for double blinding warfarin use. All other studies
were of a study design using double blind doses of the
study drug in the intervention arm against open label war-
farin in the comparison arm. There was one study OPAL-2
that was not included, this was a study of 1297 participants,
which data were not sufﬁciently reported to include.
NOACs when compared to warfarin demonstrated a
signiﬁcant reduction in the composite of stroke or sys-
temic embolic events and were at least as good as war-
farin in the prevention ischaemic stroke. There was a
notable reduction in intracranial haemorrhage of 52%
with the true population effect of between 60% and
43% reduction. This was the main driver of the 14%
reduction in mortality.
Pooled data for the composite of major or clinically
relevant non-major bleeding showed signiﬁcant
Figure 4 Intracranial haemorrhage fixed effects model.
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heterogeneity, a ﬁxed effects model indicated that
NOACs were superior to warfarin, however, a random
effects model indicated a non-signiﬁcant trend towards
beneﬁt. The heterogeneity is likely to have arisen from
the ROCKET AF study which included participants of a
higher bleeding risk as well as two of the phase II
studies, which had multiple study doses, the higher of
which were associated with more bleeding events.
Indeed the higher twice daily doses of study drugs were
noted to achieve higher area under the curve plasma
concentrations, with the suggestion of a non-linear
relationship between study dose and anticoagulation
making higher doses unlikely to be used in phase III
trials. There was also a signiﬁcant reduction in major
bleeding with the NOACs, however, phase II studies with
higher doses of study drugs were a source of
heterogeneity.
Only the phase III trials reported data for gastrointes-
tinal bleeding, pooled data were suggestive of a trend
towards less gastrointestinal bleeding in the warfarin
arms. There was, however, signiﬁcant heterogeneity with
the ARISTOTLE trial indicating a trend towards beneﬁt
Figure 5 Mortality fixed effects model.
Figure 6 Stroke or systemic embolism 30-day poststudy switch to warfarin fixed effects model.
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as does the J-ROCKET AF study, which had a slightly
lower study dose of 15 mg rivaroxaban once daily rather
than the 20 mg once daily dose used in ROCKET AF.
There was signiﬁcantly more gastrointestinal bleeding in
ROCKET AF and the higher dose of dabigatran (rando-
mised evaluation of long-term anticoagulant therapy,
RE-LY) and a non-signiﬁcant trend towards harm in the
higher dose edoxaban (ENGAGE TIMI AF 48) and
lower dose dabigatran (RE-LY). The lower dose edoxa-
ban (ENGAGE TIMI AF 48) showed signiﬁcantly less
gastrointestinal bleeding.
ROCKET AF did include participants with a higher
bleeding risk and interestingly the RE-LY trial authors
noted that a low pH is required for absorption of dabiga-
tran and that “dabigatran capsules contain dabigatran-
coated pellets with a tartaric acid core.” Tartaric acid is
found in wine and contributes to its acidity, whether or
not this contributes to gastrointestinal bleeding is
unclear.
RE-LY did note signiﬁcantly more dyspepsia in both
dabigatran doses than warfarin, which was the most
likely adverse reaction leading to discontinuation of the
study drug and contributed to the approximate 5%
higher discontinuation of dabigatran compared to war-
farin at both 1 and 2 years.
Two of the large phase three studies use two study
doses, this could certainly be justiﬁed to help under-
stand if particular patient subgroups would beneﬁt from
the lower or higher dose as well as the relative effective-
ness and safety of each. However, this could also confer
the additional advantage when the results are pooled of
the beneﬁt of increased anticoagulation and efﬁcacy
of the higher dose and the advantageous safety proﬁle
of the lower dose.
Figure 7 Major bleeding 30-day poststudy switch to warfarin fixed effects model.
Figure 8 Grading of recommendations assessment, development and evaluation summary of findings table.
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Pooled estimates for the outcome of myocardial infarc-
tion were equivocal with a point estimate very close to
one indicating no associated increase in myocardial
infarction with NOACs. The original RE-LY data indi-
cated a signiﬁcant increase in myocardial infarction for
the lower dose of dabigatran, however, this was later
revised.20 Instead we accepted the amended data, which
clearly explained acceptable justiﬁcation for
re-evaluating and blinded assessment of the original trial
records. This should be considered in the context that
warfarin has the additional incidental beneﬁt of being
protective against MI.
There was limited post hoc data for a pooled analysis of
stroke and systemic embolism when the studies came to
an end and participants taking NOACs were switched to
warfarin. During this 30-day switch to warfarin there was a
highly signiﬁcant increase in stroke and systemic embolic
events in the NOACs. ROCKET AF reported that the
median time to INR within therapeutic range was 13 days
for the rivaroxaban arm and 3 days for the warfarin arm,
which could elucidate to the increase in embolic events
as a return to baseline risk of the warfarin naive patient.
Interestingly the most recent of the large phase III
trials ENGAGE TIMI AF 48 did not demonstrate a differ-
ence between NOACs and warfarin arms during the
30-day switch and notably had a “comprehensive transi-
tion plan to open-label anticoagulation therapy”
reported by the authors. Given the short half-life of the
NOACs it is certainly plausible that any time between
discontinuation and achieving an INR within the thera-
peutic range is a likely explanation as opposed to a tran-
sient prothrombotic state resulting from a rebound
effect and highlights the importance of very close moni-
toring during any transition.
A somewhat surprising ﬁnding was the concomitant
increase in major bleeding. ARISTOTLE, ROCKET AF
and ENGAGE TIMI AF 48 reported major bleeding for
the 30-day poststudy switch to warfarin, which showed a
signiﬁcant excess in bleeding events in the NOACs arms.
The mechanism by which this could plausibly occur
given that the NOACs have a relatively short half-life,
would seem to preclude a drug interaction and perhaps
may indicate the potentially ﬂuctuant INR levels that
can occur during the initiation of warfarin therapy. This
again may simply highlight the importance of close clin-
ical supervision during the initiation of warfarin therapy
after cessation of long-term NOAC use.
It is, however, unclear whether cessation of long-term
therapy for surgical and invasive procedures may show a
similar trend and highlights the need for timely cessa-
tion of NOACs prior to procedures and vigilant report-
ing of any thromboembolic or bleeding events.
While warfarin remains an effective drug, the NOACs
do confer the additional advantages of fewer interac-
tions with drugs and foods as well as no requirement for
routine monitoring, indeed the notion of taking a drug
manufactured solely for therapeutic use could also be
preferable to taking ‘a rat poison’.
Of course warfarin does still retain some advantages,
it has been in use for routine clinical practice for
many years and is well understood. Testing INR allows
for speciﬁc tailoring of doses for the individual and
perhaps crucially, the administration of vitamin K
effectively reverses warfarin’s anticoagulant effect.
Conversely the action of NOACs cannot be quickly
and effectively reversed, which with their increasing
use in clinical practice may leave clinicians almost
helpless to intervene when their patients experience
incidental trauma.
CONCLUSION
The NOACs are a safe and effective alternative to war-
farin for the prevention of ischaemic stroke in patients
with atrial ﬁbrillation and at least one additional risk
factor for stroke. The NOACs are at least as good as war-
farin for the prevention of ischaemic stroke and systemic
embolic events and confers the additional advantage of
halving the number of haemorrhagic strokes which
drives an overall reduction in mortality. There is also a
reduction in major bleeding events associated with the
NOACs when compared to warfarin. Cessation of long-
term NOAC use and switch to warfarin may be asso-
ciated with an increase in the composite of ischaemic
stroke and systemic embolic events as well as major
bleeding in the 30 days after cessation (ﬁgure 8), which
most likely highlights the necessity of close clinical
supervision during this period. Reporting of events
during the switch to warfarin in clinical trials is essential
in improving understanding of this, as is the reporting
of suspected adverse events during transition to warfarin
in non-clinical trial settings.
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